Navigation Links
IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

MOUNTAIN VIEW, Calif., March 4 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and full year ended January 2, 2010.

For the fourth quarter of 2009, the Company recorded a net profit of $0.5 million or $0.06 per diluted share compared to a net loss of $6.5 million or $(0.74) per diluted share for the fourth quarter of 2008. Gross margins improved to 45.6% from 37.5%, although revenue for the fourth quarter of 2009 was $11.6 million, a 4.8% decrease from the $12.1 million reported for the fourth quarter of 2008. For the fiscal year ended January 2, 2010, the Company recorded a net profit of $2.6 million or $0.29 per diluted share compared to a net loss of $7.4 million or $(0.84) per diluted share reported for 2008. Gross margins improved to 46.9% from 40.6%, although revenue for the full year 2009 was $43.2 million, an 11.0% decrease from the $48.5 million reported for 2008.

In 2008, the fourth quarter and full year results included an impairment charge of $5.4 million for write down of goodwill and intangible assets which represented $0.61 per diluted share.

"Our cash generation remains excellent. We have generated $6.8 million in cash from operations for the year. Our cash balance now stands at $9.4 million and we have reduced our bank debt from $6.0 million to $3.5 million" stated Mr. Theodore A. Boutacoff, President and CEO. "We continue to see the benefits of creating a very efficient and scalable business."

"We have recorded our fourth consecutive quarter of profitability. Our operating income for the year was $2.5 million an all time high for the Company, compared to 2008 where the Company had an operating loss of $2.2 million (excluding impairment charges). This is an outstanding achievement especially given the current economy. We are particularly pleased with the improvement in gross margins and the fact that we have sustained these improvements throughout the year, and we continue to control our operating expenses. In summary, we met our 2009 objectives of being cash flow positive, driving to profitability and positioning ourselves for future growth."

"During the fourth quarter we saw a very steady order rate for Ophthalmology Equipment which adds to our confidence for 2010. We see broadening interest in our recently introduced IQ 577 yellow laser. These facts, together with other initiatives we are undertaking, provide new growth opportunities for 2010. Looking forward, based on our performance for 2009, our financial model has our gross margins in the range of 45% to 50% with operating expenses between 40% and 42% for the year; and we are making progress towards our long term goals of 55% gross margins and 40% operating expenses."

Conference Call

IRIDEX management will conduct a conference call later today, Thursday, March 4, 2010 at 5:00 p.m. Eastern Time.  Interested parties may access the live conference call via telephone by dialing (877) 941-8609 (U.S.) or (480) 629-9818 (International) and quoting Conference ID 4244509, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, March 4, 2010 through Thursday, March 11, 2010 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4244509. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's scalable business model, operating expense controls, product demand, growth strategy and prospects, and expected gross margin and operating expense levels for 2010 and in the longer term.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Quarterly Report on From 10-Q for the quarter ended October 3, 2009 and our Annual Report on Form 10-K for the fiscal year ended January 3, 2009, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

    
    
                                IRIDEX Corporation
                  Condensed Consolidated Statements of Operations
                         (In thousands, except per share data)
                                    (unaudited)
    
                              Three Months Ended      Twelve Months Ended  
                             January 2,  January 3,  January 2,  January 3, 
                                2010        2009        2010        2009 
                                ----        ----        ----        ---- 
                                                                          
    Revenues                  $11,563     $12,145     $43,212     $48,528 
    Cost of revenues            6,289       7,592      22,939      28,849 
                                -----       -----      ------      ------ 
        Gross profit            5,274       4,553      20,273      19,679 
                                -----       -----      ------      ------ 
                                                                          
    Operating expenses:                                                   
      Research and                                                        
       development                974       1,015       3,609       4,009 
      Sales and marketing       2,507       2,987       9,273      10,998 
      General and                                                         
       administrative           1,006       1,498       4,873       6,844 
      Impairment of                                                       
       goodwill and                                                       
       intangible assets            -       5,364           -       5,364 
                                  ---       -----         ---       ----- 
        Total operating                                                   
         expenses               4,487      10,864      17,755      27,215 
                                -----      ------      ------      ------ 
                                                                          
    Income (loss) from                                                    
     operations                   787      (6,311)      2,518      (7,536)
       Legal settlement             -           -         800         800 
      Interest and other                                                  
       expense, net               (40)        (81)       (237)       (507)
                                  ---         ---        ----        ---- 
    Income (loss) before                                                  
     income taxes                 747      (6,392)      3,081      (7,243)
      Provision for income                                                
       taxes                      230         111         496         127 
                                  ---         ---         ---         --- 
    Net income (loss)            $517     $(6,503)     $2,585     $(7,370)
                                 ====     =======      ======     ======= 
                                                                          
                                                                          
    Net income (loss)                                                     
     per share - basic          $0.06      $(0.74)      $0.29      $(0.84)
                                =====      ======       =====      ====== 
    Net income (loss)                                                     
     per share - diluted        $0.06      $(0.74)      $0.29      $(0.84)
                                =====      ======       =====      ====== 
                                                                          
    Shares used in                                                        
     computing net                                                        
     income (loss) per                                                    
     share - basic              8,847       8,824       8,840       8,824 
                                =====       =====       =====       ===== 
    Shares used in                                                        
     computing net                                                        
     income (loss) per                                                    
     share - diluted            8,928       8,824       8,940       8,824 
                                =====       =====       =====       ===== 
    
    
    
                                IRIDEX Corporation
                       Condensed Consolidated Balance Sheets
                                  (In thousands)
                                   (unaudited)
    
                                                      January 2,  January 3, 
                                                         2010        2009 
                                                         ----        ---- 
                        Assets                       (unaudited)           
                        ------                                             
    Current Assets:                                                        
      Cash and cash equivalents                         $9,378      $5,307 
      Accounts receivable, net                           7,482       8,199 
      Inventories, net                                   8,999      11,644 
      Prepaids and other current assets                    470         540 
                                                           ---         --- 
        Total current assets                            26,329      25,690 
       Property and equipment, net                         486         832 
       Other intangible assets, net                      1,153       1,474 
      Other long term assets                               323         229 
                                                           ---         --- 
        Total assets                                   $28,291     $28,225 
                                                       =======     ======= 
                                                                           
                                                                           
         Liabilities and Stockholders' Equity                              
         ------------------------------------                              
    Current Liabilities:                                                   
      Accounts payable                                  $1,872      $2,415 
      Bank line of credit                                3,520       6,000 
      Accrued compensation                               2,171       1,729 
      Accrued expenses                                   1,983       2,249 
      Accrued warranty                                   1,165       1,345 
      Deferred revenue                                   2,405       2,741 
                                                         -----       ----- 
        Total current liabilities                       13,116      16,479 
                                                                           
    Long Term Liabilties:                                                  
      Deferred rent                                        149           - 
                                                           ---         --- 
    Total liabilities                                   13,265      16,479 
                                                                           
    Stockholders' Equity:                                                  
       Convertible preferred stock                           5           5 
      Common Stock                                          89          89 
      Additional paid-in capital                        39,820      39,105 
      Accumulated other comprehensive loss                (212)       (192)
      Treasury stock, at cost                             (430)       (430)
      Accumulated deficit                              (24,246)    (26,831)
                                                       -------     ------- 
        Total stockholders' equity                      15,026      11,746 
                                                        ------      ------ 
        Total liabilities and stockholders' equity     $28,291     $28,225 
                                                       =======     ======= 
    
    
    

SOURCE IRIDEX Corporation

Back to top

RELATED LINKS
http://www.iridex.com

'/>"/>

SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
2. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
3. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
4. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):